Jason Adair
Chief Business Officer
Replay available
Liquidia Corporation (NASDAQ: LQDA) Q2 2026 earnings conference call, held 2026-08-12. Replay captured from the company's public earnings webcast.

Chief Business Officer
Chief Executive Officer
Chief Operating Officer and Chief Financial Officer
Analyst, Jefferies
Chief Medical Officer
Chief Commercial Officer
Analyst, BTIG
Analyst, Raymond James
Watch the replay and follow the connected company analysis, news, and investor updates for Liquidia Corporation.
WEBVTT 00:00:00.031 -- 00:00:05.493 Good morning and welcome to the Liquidia Corporation second quarter 2026 financial 00:00:05.493 -- 00:00:07.974 results and corporate update conference call. 00:00:07.974 -- 00:00:10.875 My name is Daniel and I will be your operator today. 00:00:10.875 -- 00:00:13.836 All participants are currently in listen only mode. 00:00:13.836 -- 00:00:17.618 Following the presentation, we will conduct a question and answer session. 00:00:17.618 -- 00:00:21.139 Instructions for joining the queue will be provided at that time. 00:00:21.139 -- 00:00:24.380 Please note that today's call is being recorded. 00:00:24.380 -- 00:00:30.082 I'll now turn the call over to Jason Adair, Liquidia's chief business officer. 00:00:32.589 -- 00:00:36.230 Thank you and good morning, everyone. It's my pleasure to welcome you to our second quarter 00:00:36.230 -- 00:00:39.411 2026 financial result and corporate update call. 00:00:39.411 -- 00:00:44.212 Joining me today are Dr. Roger Jeffs, Chief Executive Officer, Michael Kaseta, Chief 00:00:44.212 -- 00:00:46.913 Operating Officer and Chief Financial Officer, Dr. 00:00:46.913 -- 00:00:50.834 Rajeev Saggar, Chief Medical Officer, Scott Moomaw, Chief Commercial Officer, and Rusty 00:00:50.834 -- 00:00:55.075 Schundler, General Counsel. Before we begin, please note that today's discussion will 00:00:55.075 -- 00:00:58.775 include forward-looking statements, including statements regarding future results, product 00:00:58.775 -- 00:01:01.594 performance, and ongoing clinical or commercial activities. 00:01:01.594 -- 00:01:04.795 These statements are subject to risks and uncertainties that may cause actual results 00:01:04.795 -- 00:01:09.416 to differ materially. For further information, please refer to our filings wi...